Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer

Oncotarget

Volumn 6, Issue 5, 2015, Pages 1-11

  Fujita, Yu ^a,b   Yagishita, Shigehiro ^c   Takeshita, Fumitaka ^a   Yamamoto, Yusuke ^a   Kuwano, Kazuyoshi ^b   Ochiya, Takahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Malignancy; NSCLC; RNAi; RPN2; siRNA

Indexed keywords

CISPLATIN; DOCETAXEL; MESSENGER RNA; REGULATOR PROTEIN; RIBOPHORIN II; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CELL INVASION; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS; DRUG SENSITIVITY; FEMALE; GENE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER CELL LINE; MAJOR CLINICAL STUDY; MALE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; RIBOPHORIN II GENE; SURVIVAL TIME; TUMOR GROWTH; TUMOR RECURRENCE; VALIDATION STUDY;

EID: 84923284331     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 2011; 61:91-112.
2. Cheng H, Xu X, Costa DB, Powell CA, Halmos B. Molecular testing in lung cancer: the time is now. Current oncology reports. 2010; 12:335-348.
3. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12:175-180.
4. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007; 8:173-184.
5. Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011; 12:329-340.
6. Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K, Ochiya T. RPN2 gene confers docetaxel resistance in breast cancer. Nature medicine. 2008; 14:939-948.
7. Takahashi RU, Takeshita F, Honma K, Ono M, Kato K, Ochiya T. Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3beta. Scientific reports. 2013; 3:2474.
8. Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Nagai Y, Ishimoto T, Baba Y, Mimori K, Baba H. RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma. British journal of cancer. 2012; 107:1233-1238.
9. Zhu J, He J, Liu Y, Simeone DM, Lubman DM. Identification of glycoprotein markers for pancreatic cancer CD24+CD44+ stem-like cells using nano-LC-MS/MS and tissue microarray. J Proteome Res. 2012; 11:2272-2281.
10. Fujita Y, Takeshita F, Mizutani T, Ohgi T, Kuwano K, Ochiya T. A novel platform to enable inhaled naked RNAi medicine for lung cancer. Scientific reports. 2013; 3:3325.
11. Fujiwara T, Takahashi RU, Kosaka N, Nezu Y, Kawai A, Ozaki T, Ochiya T. RPN2 Gene Confers Osteosarcoma Cell Malignant Phenotypes and Determines Clinical Prognosis. Molecular therapy Nucleic acids. 2014; 3:e189.
12. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene. 2004; 23:2934-2949.
13. Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell death and differentiation. 2011; 18:1414-1424.
14. Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S, Wang XY, Dent P, Reed JC, Pellecchia M, Sarkar D, Fisher PB. Targeting the Bcl-2 family for cancer therapy. Expert opinion on therapeutic targets. 2013; 17:61-75.
15. Tominaga N, Hagiwara K, Kosaka N, Honma K, Nakagama H, Ochiya T. RPN2-mediated glycosylation of tetraspanin CD63 regulates breast cancer cell malignancy. Molecular cancer. 2014; 13:134.
16. Radford KJ, Mallesch J, Hersey P. Suppression of human melanoma cell growth and metastasis by the melanomaassociated antigen CD63 (ME491). International journal of cancer Journal international du cancer. 1995; 62:631-635.
17. Takeshita F, Ochiya T. Therapeutic potential of RNA interference against cancer. Cancer science. 2006; 97:689-696.
18. Boudreau RL, Martins I, Davidson BL. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther. 2009; 17: 169-175.
19. Fujita Y, Takeshita F, Kuwano K, Ochiya T. RNAi Therapeutic Platforms for Lung Diseases. Pharmaceuticals. 2013; 6:223-250.
20. Onn A, Isobe T, Itasaka S, Wu W, O'Reilly MS, Ki Hong W, Fidler IJ, Herbst RS. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res. 2003; 9:5532-5539.